Profile
Valerie Salentey is currently the Director of Regulatory Affairs & Quality Assurance at Sensorion SA since 2020.
Prior to this, she worked as the Head of Regulatory Affairs at Neovacs SA from 2018 to 2020, Head of Regulatory Affairs at PPD France SAS in 2018, and Head of Regulatory Affairs at Genethon from 2016 to 2018.
She also worked as the Head of Regulatory Affairs at Cytheris SA from 2008 to 2013.
Valerie Salentey active positions
| Companies | Position | Start |
|---|---|---|
| SENSORION | General Counsel | 01/04/2020 |
Former positions of Valerie Salentey
| Companies | Position | End |
|---|---|---|
| NEOVACS | General Counsel | 01/03/2020 |
PPD France SAS
PPD France SAS Miscellaneous Commercial ServicesCommercial Services Provides technical analyzes,tests and inspection services | General Counsel | 01/10/2018 |
Genethon
Genethon BiotechnologyHealth Technology Develops gene therapy products for rare diseases | General Counsel | 01/01/2018 |
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for immune modulation | General Counsel | 01/08/2013 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for immune modulation | Health Technology |
Neovacs SA
Neovacs SA Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapies | Health Technology |
PPD France SAS
PPD France SAS Miscellaneous Commercial ServicesCommercial Services Provides technical analyzes,tests and inspection services | Commercial Services |
Sensorion SA
Sensorion SA Pharmaceuticals: MajorHealth Technology Operates as a research and development company that discovers drugs to treat inner ear disorders | Health Technology |
Genethon
Genethon BiotechnologyHealth Technology Develops gene therapy products for rare diseases | Health Technology |
- Stock Market
- Insiders
- Valerie Salentey
















